Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03899285
Other study ID # 2018-1215
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 8, 2018
Est. completion date December 8, 2018

Study information

Verified date April 2019
Source Ciusss de L'Est de l'Île de Montréal
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Major depressive disorder is a common mental disorder and the leading cause of disability worldwide. According to the Canadian Network for Mood and Anxiety Treatment, early improvement following an antidepressant treatment is correlated with response and remission. Escalation of an antidepressant dose after 2 weeks, as opposed to 4 to 8 weeks, is proposed to favor early improvement. However, this has never been tested systematically in a controlled study involving major depressive disorder patients that are non-responders to their antidepressant treatment.


Description:

The investigators sought to assess whether it is feasible to perform a prospective randomized controlled double-blind feasibility study with a 2 week run-in period and 3 parallel groups randomized controlled study using citalopram. Citalopram has physicochemical properties compatible with over-encapsulation and a has a simple titration that allows the study of early dose increase.. It is among the most prescribed antidepressant in the province of Quebec and at the Hospital Maisonneuve-Rosemont - University family medicine group (U-FMG).

Since establishment of a randomized controlled trial is complex and expensive, a feasibility design is appropriate to identify all the obstacles and to minimize sources of possible bias (recruitment, follow up, resources).


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date December 8, 2018
Est. primary completion date December 8, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Understand french or english

- Primary diagnostic of major depressive disorder based on the Diagnostic and Statistical Manual of Mental Disorders criteria (5th edition)

- Prescription of citalopram

- Citalopram started less than 4 days ago

- Able to receive informed consent

- Not participating to another study

Exclusion Criteria:

- Pregnancy or breastfeeding

- Unable to participate to follow-up

- Hypersensitivity to citalopram or any component of the formulation

- Known QT interval prolongation or congenital long QT syndrome

- Hepatic impairment (Child Pugh A, B or C)

- Renal impairment (Clcr < 30 ml/min)

- Known cytochrome P450 2C19 poor metabolizers

- History of non-response to citalopram

- Head trauma or severe cognitive impairment

- Substance-related and addictive disorders controlled less than 3 months or uncontrolled

- Schizophrenia or psychotic disorder

- Mixed depression

- History of manic/hypomanic episodes

- Use of prohibited drugs : monoamine oxidase inhibitors, cytochrome P450 2C19 inhibitors, drugs at risk of causing prolongation of the QT interval, cimetidine, pimozide and antidepressors taken for another psychiatric condition.

Study Design


Intervention

Drug:
Citalopram 20mg or 40 mg (phase 2)
For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.

Locations

Country Name City State
Canada GMF-U Maisonneuve-Rosemont hospital Montréal-Est Quebec

Sponsors (1)

Lead Sponsor Collaborator
Ciusss de L'Est de l'Île de Montréal

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary outcomes determined by the proportion of non-responders (< 30 % improvement on the MADRS) after 2 weeks of treatment and the proportion of non-responders randomized patients who completed the study. The efficacy of treatment was assessed by the Montgomery and Asberg Depression Rating Scale (MADRS).Threshold for non-responders : < 30 % improvement on the MADRS between T2 and T0. This scale was completed by a trained assessor and measures the severity of depressive episodes in patients with mood disorders. The scale is in french and has 10 items, with an overall score ranging from 0 to 60 points. Higher score indicates more severe depression.
Criteria for success of the randomization and completion of the study :
Sample size target : 24 non-responders randomized patients
Proportion of non-responders after 2 weeks of treatment (T2) : = 0.45 (number of non-responders after 2 weeks of treatment divided by the number of enrolled patients).
Proportion of non-responders randomized patients who completed the full course of treatment (8 weeks) : = 0.65 (number of non-responders randomized patients who completed the study divided by the total number of enrolled patients).
8 weeks
Secondary Proportion of eligible subjects Number of subjects who meet the eligibility criteria divided by the total number of patients referred to the study team. 8 weeks
Secondary Recruitment rate Number of enrolled patients divided by total number of patients who meet the eligibility criteria. 8 weeks
Secondary Retention rate Total number of patients who completed the full course of study divided by the number of enrolled patients.
A descriptive analyse will be performed to identify the reasons of prematures departures.
8 weeks
Secondary Adherence rate to treatment Assessed with pill count reported to the research pharmacy at each follow-up in clinic (T2, T4, T6 and T8). 8 weeks
Secondary Unblinding rate Number of unblinded patients divided by the total number of enrolled patients.
A descriptive analyse will be performed to identify the reasons of unblinding.
8 weeks
Secondary Length of interviews An average of all the interviews will be calculated (in minutes). 8 weeks
Secondary Side effects reported to the assessors and measured by the Frequency, Intensity, and Burden of Side Effect Rating (FIBSER). The side effects were reported to assessor and their gravity were measured by a self-administrated scale called the FIBSER.The FIBSER is composed of 3 questions and takes 3 distinct aspects : frequency, intensity and the burden of side effect on the quality of life. The scale was in french and has 3 questions, with an overall score ranging from 0 to 18 points. Higher score indicates a high side-effect burden that should be evaluated. 8 weeks
Secondary Response curves for all patients according to the results from the MADRS. Compare the clinical response following the increase of citalopram at 2 weeks (group A) or 4 weeks (group B) in non-responder patients according to the results from the Montgomery and Asberg Depression Rating Scale (MADRS) at T2, T4, T6 and T8.
This scale was completed by a trained assessor and measures the severity of depressive episodes in patients with mood disorders. The scale is in french and has 10 items, with an overall score ranging from 0 to 60 points. Higher score indicates more severe depression.
8 weeks
Secondary Correlation between the results of Patient Health Questionnaire-9 (PHQ-9) and the MADRS at each follow-up (T2, T4, T6 and T8). A pearson coefficient to describe the correlation (r) between the PHQ-9 and the Montgomery and Asberg Depression Rating Scale (MADRS) was chosen.
The PHQ-9 is a questionnaire self-reported assessing the severity of the depression. The scale was in french and has 9 items, with an overall score ranging from 0 to 27 points. Higher score indicates more severe depression.
The MADRS was completed by a trained assessor and measures the severity of depressive episodes in patients with mood disorders. The scale is in french and has 10 items, with an overall score ranging from 0 to 60 points. Higher score indicates more severe depression.
8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A